Uncategorized

[Oligomerix, Inc. (Business Wire)] Oligomerix, Inc. announced an National Institutes of Health (NIH) Fast Track Phase II award of $1.9 million from the National Institute on Aging of the NIH.

[Nature] Researchers found that neurons routinely sustain DNA breaks during cortex formation, but a rapid repair system corrects the damage before harm occurs.

[Autophagy] Using integrated transcriptomic and epigenomic analyses, scientists identified EGR1 as a critical regulator of traumatic brain injury pathology, with its expression acutely upregulated in neurons post-injury.

[Proceedings of the National Academy of Sciences of the United States of America] Investigators identified embigin (EMB) as a critical regulator of enteric neuronal maturation. In EMB mutant patients, the expression of EMB is reduced in the enteric neurons of the hypoganglionosis-affected colon.

[Cell Death & Disease] By integrating multiomics profiling with functional assays in patient-derived glioblastoma cells, orthotopic xenografts, and clinical specimens, scientists aimed to elucidate the role of hypoxia-induced hsa_circ_0000745 (circSPECC1) in mediating temozolomide resistance.

[Cell Death & Disease] The authors investigated how neurons respond to genotoxic stress induced by quarfloxin (CX-3543), a small molecule that stabilizes G-quadruplexes.They found that quarfloxin treatment induced DNA damage in neurons, with double-strand breaks enriched in the nucleolus.

[Cell Chemical Biology] Through neuron-like and glia-like co-culture models, researchers identified a neuron’s protective mechanism mediated by membrane-associated glycoRNAs.

[Reviews in the Neurosciences] Scientists address the most recent molecular mechanisms of GDF11 signaling in the regulation of neural stem cell, linking TGF-β signaling, neurogenesis, and brain aging.

[University of Maryland Baltimore] The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is the first in the Maryland, Delaware, Virginia, and Washington, D.C., region to offer a cell therapy treatment for patients with an advanced type of soft tissue cancer, known as synovial sarcoma.

[Oncology News Central] The US FDA has fully approved afamitresgene autoleucel and expanded its indication to include patients aged 12 years and older with unresectable or metastatic synovial sarcoma whose disease has progressed after chemotherapy.

[Nature Communications] Researchers performed comprehensive multi-omic profiling of an unselected perivascular epithelioid cell neoplasm cohort. Transcriptomic analysis defined four subtypes with distinct lineage programs—melanocytic, mesenchymal, or adipogenic—as well as unique mutational patterns and clinical behaviors.

[International Immunopharmacology] In the past 20 years, MSCs have emerged as attractive treatment options for osteoporosis due to their capacity to differentiate into osteoblasts, modulate immune responses, and exert paracrine effects.